Andrea Navarria

Andrea Navarria

Auto-generated profile, based on publicly available information

Andrea Navarria

Novo Nordisk A/S , 2860 Søborg

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in The Lancet Diabetes & Endocrinology
Verified
Journal Article
Closed access
RPRichard E. Pratley
Richard E. Pratley
VAVanita R Aroda
Vanita R Aroda
ILIldiko Lingvay
Ildiko Lingvay
JLJörg Lüdemann
Jörg Lüdemann
CACamilla Andreassen
Camilla Andreassen
AVAdie Viljoen
Adie Viljoen

1 November 2013 in Biological Psychiatry
Verified
Journal Article
Closed access
BVBhavya Voleti
Bhavya Voleti
ANAndrea Navarria
Andrea Navarria
RLRong-Jian Liu
Rong-Jian Liu
MBMounira Banasr
Mounira Banasr
NLNanxin Li
Nanxin Li
RDRonald S. Duman
Ronald S. Duman

1 October 2015 in Neurobiology of Disease
Verified
Journal Article
Closed access
ANAndrea Navarria
Andrea Navarria
EWEric S. Wohleb
Eric S. Wohleb
BVBhavya Voleti
Bhavya Voleti
KOKristie T. Ota
Kristie T. Ota
SDSophie Dutheil
Sophie Dutheil
RDRonald S. Duman
Ronald S. Duman

1 September 2014 in Pharmacological Research
Verified
Journal Article
Closed access
ANAndrea Navarria
Andrea Navarria
ATAlessandra Tamburella
Alessandra Tamburella
Fabio Arturo IannottiFabio Arturo Iannotti
Fabio Arturo Iannotti
VMVincenzo Micale
Vincenzo Micale
GCGiovanni Camillieri
Giovanni Camillieri
Vincenzo Di MarzoVincenzo Di Marzo
Vincenzo Di Marzo

1 January 2015 in Value in Health
Verified
Journal Article
Open access
ANAndrea Navarria
Andrea Navarria
VDValentina Drago
Valentina Drago
Lucia GozzoLucia Gozzo
Lucia Gozzo
LLLaura Longo
Laura Longo
SMSilvana Mansueto
Silvana Mansueto
Filippo DragoFilippo Drago
Filippo Drago
BackgroundDrug costs have risen rapidly in the last decade, driving third-party payers to adopt performance-based agreements that provide either a discount before payment or an ex post reimbursement on the basis of treatments’ effectiveness and/or safety issues.ObjectivesThis article analyses the strategies currently approved in Italy and proposes a novel model called “success fee” to improve payment-by-result schemes and to guarantee patients rapid access to novel therapies.MethodsA review of the existing risk-sharing schemes in Italy has been performed, and data provided by the Italian National report (2012) on drug use have been analyzed to assess the impact on drug expenditure deriving from the application of “traditional” performance-based strategies since their introduction in 2006.ResultsSuch schemes have poorly contributed to the fulfillment of the purpose in Italy, producing a trifling refund, compared with relevant drugs costs for the National Health System : €121 million out of a total of €3696 million paid. The novel risk-sharing agreement called “success fee” has been adopted for a new high-cost therapy approved for idiopathic pulmonary fibrosis, pirfenidone, and consists of an ex post payment made by the National Health System to the manufacturer for those patients who received a real benefit from treatment.Conclusions“Success fee” represents an effective strategy to promote value-based pricing, making available to patients a rapid access to innovative and expensive therapies, with an affordable impact on drug expenditure and, simultaneously, ensuring third-party payers to share with manufacturers the risk deriving from uncertain safety and effectiveness

1 October 2009 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
ATAlessandra Tamburella
Alessandra Tamburella
VMVincenzo Micale
Vincenzo Micale
ANAndrea Navarria
Andrea Navarria
Filippo DragoFilippo Drago
Filippo Drago